296 related articles for article (PubMed ID: 30760164)
21. Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature.
Grainger BT; Issa S
J Clin Neurosci; 2020 Jan; 71():277-280. PubMed ID: 31862225
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenström's Macroglobulinemia.
Sekiguchi N
Intern Med; 2022 Dec; 61(23):3473-3474. PubMed ID: 35569973
[No Abstract] [Full Text] [Related]
23. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
24. Bing-Neel syndrome - Bilateral cavernous sinus lymphoma causing visual failure.
Pham C; Griffiths JD; Kam A; Hunn MK
J Clin Neurosci; 2017 Nov; 45():134-135. PubMed ID: 28765059
[TBL] [Abstract][Full Text] [Related]
25. Bing-Neel Syndrome: Illustrative Cases and Comprehensive Review of the Literature.
Varettoni M; Defrancesco I; Diamanti L; Marchioni E; Farina LM; Pichiecchio A
Mediterr J Hematol Infect Dis; 2017; 9(1):e2017061. PubMed ID: 29181138
[TBL] [Abstract][Full Text] [Related]
26. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
27.
Illarramendi OA; Flynt L; Wong F
J Nucl Med Technol; 2019 Dec; 47(4):343-344. PubMed ID: 31182662
[TBL] [Abstract][Full Text] [Related]
28. Evaluation and Management of Bing-Neel Syndrome.
Schep SJ; Vos JMI; Minnema MC
Hematol Oncol Clin North Am; 2023 Aug; 37(4):777-786. PubMed ID: 37258354
[TBL] [Abstract][Full Text] [Related]
29. Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
Tripathi A; Steingart R
J Oncol Pract; 2016 May; 12(5):490-1. PubMed ID: 27170696
[No Abstract] [Full Text] [Related]
30. [Bing-Neel syndrome: Report of 4 cases and literature review].
Boudin L; Romeo E; Mavrovi E; Tsitsi Nding P; Blade JS; de Jaureguiberry JP; Gisserot O
Rev Med Interne; 2015 Jun; 36(6):418-22. PubMed ID: 24907109
[TBL] [Abstract][Full Text] [Related]
31. Bing-Neel Syndrome: An Initial Manifestation of Waldenstrom Macroglobulinemia.
Lee MS; Sathe S; Valasapalli S; Grosse Perdekamp M
Cureus; 2021 Nov; 13(11):e19402. PubMed ID: 34926004
[TBL] [Abstract][Full Text] [Related]
32. Bing-Neel syndrome: a case report and systematic review of clinical manifestations, diagnosis, and treatment options.
Grewal JS; Brar PK; Sahijdak WM; Tworek JA; Chottiner EG
Clin Lymphoma Myeloma; 2009 Dec; 9(6):462-6. PubMed ID: 19951888
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Treon SP
Haematologica; 2018 Jul; 103(7):e307-e310. PubMed ID: 29472352
[No Abstract] [Full Text] [Related]
34. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
35. An Autopsy Case of Bing-Neel Syndrome: Discrepancy between the Radiological and Pathological Findings.
Matsuda S; Sekiguchi N; Ito K; Takaoka K; Furuki M; Hirano K; Obayashi M
Intern Med; 2019 Jul; 58(13):1947-1951. PubMed ID: 30918173
[TBL] [Abstract][Full Text] [Related]
36. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
37. Complete Response of a Young Woman With MYD88
Pabon CM; Neff JL; Forns TE; Wang J
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e809-e812. PubMed ID: 32660904
[No Abstract] [Full Text] [Related]
38. Central Nervous System Involvement by Waldenstrom Macroglobulinemia: A Case Report of the Bing-Neel Syndrome.
Arjunan A; Rai H
Case Rep Hematol; 2019; 2019():4075960. PubMed ID: 31001436
[TBL] [Abstract][Full Text] [Related]
39. Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more.
Tohidi-Esfahani I; Trotman J
Br J Haematol; 2023 Jun; 201(5):807-808. PubMed ID: 36715656
[TBL] [Abstract][Full Text] [Related]
40. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Vos JM; Tsakmaklis N; Patterson CJ; Meid K; Castillo JJ; Brodsky P; Ganz T; Pals ST; Kersten MJ; Xu L; Yang G; Treon SP; Hunter ZR
Haematologica; 2017 Nov; 102(11):e452-e455. PubMed ID: 28798070
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
